The Chemours Company (NYSE:CC – Get Free Report) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 10,530,000 shares, an increase of 19.5% from the February 28th total of 8,810,000 shares. Based on an average daily volume of 2,500,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 7.1% of the company’s stock are short sold.
Analyst Ratings Changes
CC has been the subject of several research analyst reports. Barclays lowered their target price on shares of Chemours from $19.00 to $16.00 and set an “equal weight” rating for the company in a report on Tuesday. The Goldman Sachs Group cut their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Morgan Stanley cut their price target on Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Mizuho upgraded shares of Chemours from a “neutral” rating to an “outperform” rating and set a $19.00 target price on the stock in a research report on Thursday, March 27th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $22.56.
Get Our Latest Stock Analysis on CC
Institutional Inflows and Outflows
Chemours Trading Down 12.6 %
Shares of CC opened at $11.42 on Friday. Chemours has a 1-year low of $11.33 and a 1-year high of $29.21. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 20.03 and a beta of 1.84. The firm has a 50 day simple moving average of $15.85 and a 200-day simple moving average of $18.07. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92.
Chemours (NYSE:CC – Get Free Report) last released its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.36 billion for the quarter, compared to the consensus estimate of $1.37 billion. Equities analysts forecast that Chemours will post 2.03 EPS for the current fiscal year.
Chemours Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a yield of 8.76%. Chemours’s dividend payout ratio is presently 175.44%.
About Chemours
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Stories
- Five stocks we like better than Chemours
- How to Use the MarketBeat Excel Dividend Calculator
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- What is MarketRank™? How to Use it
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- What is a SEC Filing?
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.